{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T05:10:20Z","timestamp":1696482620653},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,8,11]],"date-time":"2014-08-11T00:00:00Z","timestamp":1407715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prior studies found bendamustine is efficacious in patients with indolent B\u2010cell non\u2010Hodgkin lymphoma (NHL). To date, no studies have reported the efficacy of bendamustine in a Chinese population. This multicentre phase II trial evaluated the pharmacokinetics (PK), safety and efficacy of bendamustine monotherapy in Chinese patients in Taiwan with pretreated indolent B\u2010cell NHL or mantle cell lymphoma (MCL). For PK assessments, patients were randomized (<jats:italic>n<\/jats:italic>\u2009=\u200916; 11 with indolent B\u2010cell NHL and five with MCL) to 90 or 120\u2009mg\/m<jats:sup>2<\/jats:sup> of bendamustine for the first cycle. Plasma levels of bendamustine and its two metabolites were analyzed. For efficacy and safety evaluations, bendamustine 120\u2009mg\/m<jats:sup>2<\/jats:sup> was given to all patients every 3\u2009weeks starting at cycle 2 for a minimum of a total of six cycles. The median age of patients was 61.7\u2009years, and the majority were men (75%). The median number of prior treatments was 4 (range, 1\u20139 regimens), and all patients were previously treated with rituximab. Bendamustine plasma concentration peaked near the end of infusion and was rapidly eliminated with a mean elimination half\u2010life (<jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub>) of 0.67\u20130.8\u2009h. Of the evaluable patients (<jats:italic>n<\/jats:italic>\u2009=\u200914), the overall response rate was 78.6%, including 7.2% of patients having a complete response. Mean progression\u2010free survival was 27.5\u2009weeks. The most common grade 3\u20134 adverse events were leucopenia (56.3%), neutropenia (56.3%) and thrombocytopenia (25%). In conclusion, bendamustine was efficacious and well tolerated in Taiwanese patients with indolent NHL and MCL with a similar PK profile to that of other populations. Copyright \u00a9 2014 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2161","type":"journal-article","created":{"date-parts":[[2014,8,11]],"date-time":"2014-08-11T11:30:07Z","timestamp":1407756607000},"page":"136-144","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B\u2010cell non\u2010Hodgkin lymphoma and mantle cell lymphoma"],"prefix":"10.1002","volume":"33","author":[{"given":"Liang\u2010Tsai","family":"Hsiao","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Taipei Veterans General Hospital and National Yang\u2010Ming University School of Medicine  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwei\u2010Fang","family":"Tien","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine National Taiwan University Hospital, College of Medicine, National Taiwan University  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching\u2010Yuan","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine  Kaohsiung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin\u2010Hou","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine Taipei Chang Gung Memorial Hospital  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin\u2010An","family":"Hou","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine National Taiwan University Hospital, College of Medicine, National Taiwan University  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming\u2010Chung","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine  Kaohsiung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun\u2010Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Taipei Veterans General Hospital and National Yang\u2010Ming University School of Medicine  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po\u2010Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Taipei Veterans General Hospital and National Yang\u2010Ming University School of Medicine  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzeon\u2010Jye","family":"Chiou","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Department of Medicine Taipei Veterans General Hospital and National Yang\u2010Ming University School of Medicine  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,8,11]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Cancer facts & figures.2013.http:\/\/www.cancer.org\/acs\/groups\/content\/@epidemiologysurveilance\/documents\/document\/acspc\u2010036845.pdf. (Accessed 20 September 2013)."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22850"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-285221"},{"key":"e_1_2_7_5_1","unstructured":"General information about adult non\u2010Hodgkin lymphoma (NHL).2013.http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/adult\u2010non\u2010hodgkins\/HealthProfessional\/page1. (Accessed 20 September 2013)."},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1200\/JCO.1985.3.3.299","article-title":"Karnofsky memorial lecture. The low\u2010grade non\u2010Hodgkin's lymphomas: challenges and opportunities","volume":"3","author":"Rosenberg SA","year":"1985","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_7_1","first-page":"75","article-title":"Natural history of and therapy for the indolent non\u2010Hodgkin's lymphomas","volume":"20","author":"Horning SJ","year":"1993","journal-title":"Semin Oncol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1587"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.020"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000174039.69656.2b"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2819"},{"key":"e_1_2_7_16_1","first-page":"2253","article-title":"Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1\u2010positive MCL and cyclin D1\u2010negative MCL\u2010like B\u2010cell lymphoma","volume":"95","author":"Yatabe Y","year":"2000","journal-title":"Blood"},{"key":"e_1_2_7_17_1","unstructured":"Mantle cell lymphoma facts.2013.http:\/\/www.lls.org\/content\/nationalcontent\/resourcecenter\/freeeducationmaterials\/lymphoma\/pdf\/mantlecelllymphoma.pdf. (Accessed 19 September 2013)."},{"key":"e_1_2_7_18_1","first-page":"485","article-title":"In vitro induction of apoptosis of neoplastic cells in low\u2010grade non\u2010Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine","volume":"86","author":"Chow KU","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402651"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24714"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01635.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0331-5"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8389"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01633.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1254-8"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-012-0001-5"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.649476"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200110000-00003"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0023-2"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2161","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T04:34:22Z","timestamp":1696394062000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,11]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1002\/hon.2161"],"URL":"https:\/\/doi.org\/10.1002\/hon.2161","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,11]]}}}